Edwards Lifesciences Corp (NYSE:EW) CEO Michael A. Mussallem sold 22,850 shares of the business’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $231.36, for a total value of $5,286,576.00. Following the sale, the chief executive officer now directly owns 69,976 shares of the company’s stock, valued at approximately $16,189,647.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Edwards Lifesciences stock opened at $231.63 on Friday. The stock’s 50-day simple moving average is $238.57 and its 200-day simple moving average is $220.29. Edwards Lifesciences Corp has a 52 week low of $145.12 and a 52 week high of $247.64. The company has a market capitalization of $48.31 billion, a price-to-earnings ratio of 49.28, a PEG ratio of 2.55 and a beta of 0.77. The company has a quick ratio of 2.74, a current ratio of 3.53 and a debt-to-equity ratio of 0.17.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $1.41 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.22 by $0.19. Edwards Lifesciences had a return on equity of 32.28% and a net margin of 18.64%. The business had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same period in the previous year, the business earned $1.07 earnings per share. The business’s revenue was up 20.7% on a year-over-year basis. On average, equities analysts expect that Edwards Lifesciences Corp will post 5.6 earnings per share for the current year.

Several analysts have issued reports on the company. Raymond James boosted their price target on Edwards Lifesciences from $255.00 to $263.00 and gave the company an “outperform” rating in a report on Friday, December 6th. Cowen reissued a “buy” rating and set a $275.00 price target on shares of Edwards Lifesciences in a report on Tuesday, December 17th. Credit Suisse Group boosted their price target on Edwards Lifesciences from $269.00 to $275.00 and gave the company an “outperform” rating in a report on Friday, December 6th. Morgan Stanley boosted their price target on Edwards Lifesciences from $248.00 to $270.00 and gave the company an “overweight” rating in a report on Friday, December 6th. Finally, Royal Bank of Canada boosted their price target on Edwards Lifesciences from $217.00 to $250.00 and gave the company an “outperform” rating in a report on Tuesday, October 22nd. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $237.17.

Several institutional investors have recently made changes to their positions in EW. Quest Capital Management Inc. ADV purchased a new stake in shares of Edwards Lifesciences in the third quarter worth about $28,000. Usca Ria LLC bought a new stake in Edwards Lifesciences during the 3rd quarter valued at $34,000. Venturi Wealth Management LLC bought a new stake in Edwards Lifesciences during the 3rd quarter valued at $50,000. San Francisco Sentry Investment Group CA grew its position in Edwards Lifesciences by 67.7% during the 3rd quarter. San Francisco Sentry Investment Group CA now owns 265 shares of the medical research company’s stock worth $58,000 after purchasing an additional 107 shares during the period. Finally, Prestige Wealth Management Group LLC acquired a new stake in Edwards Lifesciences during the 2nd quarter worth about $65,000. Institutional investors and hedge funds own 80.73% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Recommended Story: P/E Growth (PEG)

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.